Integer Holdings Corporation to Exhibit at NANS Annual Meeting

PLANO, Texas, Jan. 28, 2025 (GLOBE NEWSWIRE) —

Integer Holdings Corporation (NYSE: ITGR), one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, will join global medtech leaders and innovators in exhibiting at the North American Neuromodulation Society (NANS) Annual Meeting in Orlando, Florida, from Jan. 30 – Feb. 1, 2025. NANS attendees are invited to visit booth #213 to learn more about how Integer can serve as a strategic partner of choice in amplifying customers’ innovation and increasing speed to market.

Integer Holdings Corporation is set to make a big splash at the upcoming NANS Annual Meeting in Orlando, Florida. As one of the leading players in the medical device contract development and manufacturing industry, Integer is ready to showcase its capabilities and expertise to a global audience of medtech leaders and innovators. Attendees at the event will have the opportunity to visit booth #213 and discover how Integer can help them accelerate their innovation and bring products to market faster.

With a reputation for excellence and reliability, Integer has built a strong track record of delivering high-quality medical devices to customers around the world. By partnering with Integer, companies can leverage its extensive experience and resources to streamline their development process and stay ahead of the competition.

At the NANS Annual Meeting, Integer will be highlighting its commitment to customer satisfaction and its dedication to driving innovation in the medtech industry. Through strategic partnerships and a focus on cutting-edge technologies, Integer is poised to make a significant impact on the market and help shape the future of healthcare.

How will this affect me?

As a consumer of medical devices, partnering with Integer Holdings Corporation could mean access to innovative products and technologies that are developed more quickly and efficiently. By collaborating with a leading CDMO like Integer, companies are better positioned to bring new solutions to market that can improve patient outcomes and enhance quality of life.

How will this affect the world?

Integer’s presence at the NANS Annual Meeting signals a continued commitment to driving advancements in the medtech industry on a global scale. By showcasing its capabilities to a broad audience of industry leaders and innovators, Integer is helping to shape the future of healthcare and pave the way for new and improved medical technologies that can benefit people around the world.

Conclusion

Integer Holdings Corporation’s participation in the NANS Annual Meeting is a testament to its leadership in the medical device contract development and manufacturing industry. By connecting with key stakeholders and showcasing its expertise, Integer is poised to make a lasting impact on the market and drive innovation in healthcare. As a strategic partner of choice, Integer is well positioned to help companies accelerate their product development and bring cutting-edge solutions to market faster, ultimately benefiting consumers and advancing the field of medtech.